{"id":"W3092484545","doi":"10.1016/s1470-2045(20)30441-1","title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":587,"is_retracted":false,"has_abstract":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"Cilag; Takeda Pharmaceutical Company; AbbVie; National Cancer Institute; Merck Sharp and Dohme; Pharmacyclics; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer; Roche","keywords":"Open label; Medicine; Follicular lymphoma; Refractory (planetary science); Oncology; Internal medicine; Phases of clinical research; Follicular phase; Clinical trial; Lymphoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009282482,0.001102845,0.001847799,0.0002577018,0.0002470472,0.0009024905,0.0006234976,0.001151828,0.004745371],"category_scores_gemma":[0.0009283344,0.000327119,0.001300367,0.0002659076,0.0007359479,0.00102613,0.0002868667,0.002684715,0.0008926666],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005808901,"about_ca_system_score_gemma":0.0006429352,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006407153,"about_ca_topic_score_gemma":0.00194335,"domain_scores_codex":[0.9997262,0.000130719,0.000009944632,0.00004585708,0.00002063295,0.00006665882],"domain_scores_gemma":[0.9995522,0.0001203528,0.00008678992,0.0000377996,0.0000234179,0.0001794351],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9134678,0.007973909,0.001916254,0.001237303,0.001938875,0.0001467836,0.0001638636,0.000903415,0.009034409,0.0003742875,0.003418403,0.05942475],"study_design_scores_gemma":[0.9389725,0.05434383,0.003246079,0.00004133395,0.0004216168,0.0001412414,0.0000558006,0.0005427878,0.0004055666,0.0002745099,0.001537668,0.00001699354],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9887822,0.005539574,0.0004864171,0.000948155,0.0003351832,0.001057121,0.000885169,0.0001281742,0.001837999],"genre_scores_gemma":[0.9901788,0.002672615,0.001037909,0.0010749,0.000188765,0.001238854,0.001051921,0.00002358416,0.002532599],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004745371,"threshold_uncertainty_score":0.0158748,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1386246272526778,"score_gpt":0.3873040580453387,"score_spread":0.2486794307926609,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}